title: [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma].
abstract: Malignant lymphoma is one of the tumors that show high FDG uptake, enabling the accurate detection of small involved lesions by FDG-PET. It is useful in both initial staging and follow-up study. In initial staging, FDG-PET is superior to CT from the aspects of sensitivity and specificity, and it is reported that the therapeutic protocol has been changed in 21% of patients. In the follow-up of therapy and detection of recurrence, the accuracy of residual disease is reported to be more than 90%. Among the different pathological types of lymphoma, Hodgkin's disease and intermediate-grade NHL are typical indications because of the requirement of accurate staging in determining the therapeutic protocol. One of the shortcomings of FDG-PET is its low specificity. Combination study with PET tracers with higher specificity in tumor diagnosis such as C-11 methionine or F-18 methyltyrosine could be a way to solve this problem.
authors.affiliation: Gunma University School of Medicine, Department of Nuclear Medicine.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Higuchi
mesh_terms: D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18